Group 1: Market Overview - The Hang Seng Index experienced a two-day increase, rising over 400 points, with a closing gain of 47 points or 0.18%, ending at 26,696 points [3] - The market showed volatility, reaching a high of 26,788 before facing selling pressure, dropping to a low of 26,511 [3] - The total market turnover for the day was 210.23 billion HKD [3] Group 2: Company News - Far East Development (00035) is in discussions to sell certain rights of the Ritz-Carlton hotel in Perth to Shangri-La Group for an initial payment of 20 million AUD (approximately 101 million HKD) [10] - GAC Group (02238) has signed a comprehensive strategic cooperation agreement with CATL (03750) to enhance collaboration in smart chassis and battery swapping technologies over the next ten years [11] - JD.com (09618) reported that its daily order volume for its food delivery service exceeded 25 million, with over 200,000 merchants and more than 150,000 full-time delivery riders [12] Group 3: Industry Insights - UBS's China equity investment director noted that the valuation re-evaluation phase for Chinese stocks may have ended, with a focus shifting to fundamental factors [6][7] - JPMorgan Private Bank predicts that gold prices could exceed 5,000 USD per ounce by the end of next year, driven by purchases from central banks in emerging markets [8]

资金流入方面，港股创新药精选ETF最新资金流入流出持平。拉长时间看，近5个交易日内，合计"吸金"1070.71万元。 港股创新药精选ETF紧密跟踪恒生港股通创新药精选指数，恒生港股通创新药精选指数旨在反映可经港股通买卖，业务与创新药研究、开发及生产相关的香 港上市公司之表现。 数据显示，截至2025年10月8日，恒生港股通创新药精选指数前十大权重股分别为百济神州、中国生物制药、信达生物、石药集团、康方生物、三生制药、 翰森制药、科伦博泰生物-B、再鼎医药、诺诚健华，前十大权重股合计占比72.15%。 （文中个股仅作示例，不构成实际投资建议。基金有风险，投资需谨慎。） 截至2025年11月12日 09:51，恒生港股通创新药精选指数强势上涨3.17%，成分股百济神州上涨7.29%，映恩生物-B上涨4.74%，康方生物上涨4.63%，药捷安 康-B，三生制药等个股跟涨。港股创新药精选ETF(520690)上涨2.90%，最新价报0.92元。拉长时间看，截至2025年11月11日，港股创新药精选ETF近2周累计 上涨0.56%，涨幅排名可比基金1/2。 流动性方面，港股创新药精选ETF盘中换手8.57%，成交485 ...

Group 1 - The Hang Seng Index rose by 1.55% at the close, with significant gains in the consumer sector leading the market [1] - The consumer sector experienced a notable increase of 2.35%, with stocks like Mixue Group up by 8.98%, Pop Mart up by 8.11%, and Gu Ming up by 7.05% [3] - Other consumer stocks such as Haidilao, China Resources Beer, and Miniso also saw gains exceeding 4% [3] Group 2 - The internet sector rebounded, closing up by 1.26%, with Tencent Holdings increasing by 2.44%, Kuaishou by 2.27%, and Alibaba by 2.06% [3] - Other internet stocks like SenseTime, Meituan, and Baidu also recorded gains above 1% [3] Group 3 - The healthcare sector showed weak consolidation but had some intraday movements, closing up by 1.11% [3] - Notable healthcare stocks included JD Health, which rose by 3.28%, CSPC Pharmaceutical by 2.71%, and BeiGene by 2.63% [3] - Other healthcare stocks such as Hansoh Pharmaceutical and WuXi Biologics also saw gains above 1% [3]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.48% on November 11, with a trading volume of 854 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of November 10, 2024, the fund's latest share count was 9.675 billion, with a total size of 8.015 billion yuan, reflecting a significant increase in both share count and size compared to the previous year [1] Fund Performance - The fund's share count increased by 2347.04% and its size increased by 2021.31% from 3.95 million shares and 378 million yuan on December 31, 2024 [1] - Over the past 20 trading days, the cumulative trading amount reached 24.964 billion yuan, with an average daily trading amount of 1.248 billion yuan [1] - Year-to-date, the cumulative trading amount for 207 trading days was 244.556 billion yuan, with an average daily trading amount of 1.181 billion yuan [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 65.68% during the management period [2] - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2] - The largest holdings by percentage include BeiGene at 10.62%, CanSino Biologics at 10.55%, and Innovent Biologics at 10.21% [2]

Group 1 - The Hong Kong Stock Connect Innovation Drug ETF (159570) experienced a slight decline of 0.41% on November 11, with a total trading volume exceeding 1.5 billion yuan, marking a continuous inflow of over 1.5 billion yuan in the last 10 days [1] - As of November 10, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) surpassed 21.5 billion yuan, maintaining a leading position in terms of scale and liquidity [1] - The ETF has seen a significant increase in its net inflow, with a total of over 1.5 billion yuan in the past 10 days, indicating strong investor interest [1] Group 2 - The innovative drug sector has shown outstanding performance, with listed companies in this sector achieving a total revenue of 8.012 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 23.34% [3] - In Q3 2025, the innovative drug sector's listed companies reported a total revenue of 3.154 billion yuan, reflecting a year-on-year increase of 33.59% and a quarter-on-quarter growth of 23.75% [3] - The net profit attributable to shareholders for the innovative drug sector in Q3 2025 was -1.138 billion yuan, which is a year-on-year narrowing of 22.96% and a quarter-on-quarter narrowing of 26.01% [3] Group 3 - BeiGene has raised its full-year revenue guidance for 2025, now expecting revenue between 36.2 billion yuan and 38.1 billion yuan, driven by significant growth in product revenue and improved operational efficiency [6] - For the first three quarters of 2025, BeiGene reported revenue of 27.595 billion yuan, a year-on-year increase of 44.2%, surpassing the total revenue of 27.21 billion yuan for the entire previous year [6] - The growth in revenue is attributed to the leading position of its product, Brukinsa (Zebutinib), in the U.S. market and its continued expansion in Europe and other key global markets [6] Group 4 - The recent medical insurance negotiations involved 120 domestic and foreign enterprises, with 127 drugs participating in the basic medical insurance drug directory negotiations and 24 drugs in the commercial insurance innovative drug directory price negotiations [7] - The results of the medical insurance negotiations are expected to be announced in early December, with the new drug directory set to be implemented on January 1, 2026 [7] - This year marks the first introduction of an innovative drug directory, with a new price negotiation mechanism that facilitates coordination between pharmaceutical companies and commercial insurance [8]

流动性方面，港股创新药精选ETF盘中换手7.74%，成交4223.87万元。拉长时间看，截至11月10日，港股创新药精选ETF近1年日均成交1.20亿元。 据报道，11月10日，华润三九公告，与琅钰集团、Bioproject 达成重磅合作，拿下发作性睡病创新药铧可思(替洛利生片)在中国大陆开发与商业化权益。华 润三九这款创新药的获得，不仅将为患者带来安全治疗新选择，更标志着华润三九在罕见病赛道的布局迈出关键一步。 消息方面，近日，第76届美国肝病研究协会（AASLD）年会在美国华盛顿开幕。由上海贺普药业研发的乙肝创新药贺普拉肽临床研究取得突破性进展，以 大会报告形式公布了治疗慢性乙肝II期随机双盲临床试验结果。据介绍，该创新药通过独特的病毒进入阻断独特机制，在II期临床试验中显示可逆转"大三 阳"乙肝患者对干扰素治疗的耐药性，在部分患者实现cccDNA清除，达到国际公认乙肝治愈最高标准-灭菌性治愈（sterilising cure）。 截至2025年11月11日 14:02，恒生港股通创新药精选指数下跌0.94%。成分股方面涨跌互现，联邦制药领涨1.92%，MIRXES-B上涨1.74%，三生制药上涨 0.9 ...

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has gained 1.2% with a trading volume of 351 million yuan and a total fund size of 2.079 billion yuan as of November 10 [1] - Key performing stocks within the ETF include InnoCare Pharma-B, Bionet, and Ascletis Pharma, with respective gains of 5.4%, 4.43%, and 4.37% [1] - Conversely, stocks such as Kangzhe Pharmaceutical, MIRXES-B, and Innovent Biologics showed weaker performance, with declines of 1.28%, 0.94%, and 0.65% respectively [1] Group 2 - The innovative drug sector is identified as the largest investment opportunity in the pharmaceutical sector for 2025, with a focus on dual/multi-target drugs, chronic disease medications addressing unmet clinical needs, and ADCs [2] - There is a noted improvement in domestic and international innovative drug financing data, with an upward trend in CXO industry orders, indicating a potential recovery in valuations and performance [2] - The medical device sector is experiencing accelerated approvals for innovative products, such as the approval of the chest and abdominal aortic stent system by Xianjian Technology, which is expected to enhance long-term profit margins [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF and its linked funds passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with the top ten weighted stocks including BeiGene, China Biologic Products, and Innovent Biologics [3]

Core Viewpoint - The report from CMB International emphasizes a conservative investment approach, focusing on undervalued stocks in the healthcare sector, particularly in the context of recent market fluctuations and recovery in capital financing [1] Group 1: Market Performance - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24.0% [1] - The healthcare sector has recently experienced a pullback, with the MSCI China Healthcare Index declining by 10% since October [1] Group 2: Investment Opportunities - CMB International identifies several stocks with attractive valuations, including Solid Biosciences (02273), Three-Sixty Biopharma (01530), Giant Biologics (02367), WuXi AppTec (02268), Innovent Biologics (01801), and China Biologic Products (01177) [1] - The report highlights a significant buyback plan from Solid Biosciences, which has repurchased HKD 350 million worth of shares this year, with a total expected return from buybacks and dividends reaching 7% [1] Group 3: Clinical Development and Regulatory Environment - The report stresses the importance of overseas clinical progress for authorized drug pipelines, which is expected to be a catalyst for stock price increases [2] - Three-Sixty Biopharma's collaboration with Pfizer is noted, with two global Phase 3 clinical trials for its drug 707 targeting non-small cell lung cancer and colorectal cancer [2] Group 4: Healthcare Policy and Market Dynamics - The recent healthcare negotiations and the 11th batch of centralized procurement have seen reduced market attention, with 127 drugs participating in negotiations and 55 drugs included in the procurement [3] - The new procurement rules focus on maintaining clinical stability and quality, indicating a shift towards rational price competition in the market [3] - Despite the reduced focus on procurement, the domestic market performance remains a critical variable for overall business performance [3]

Summary of Hansoh Pharma (3692.HK) Conference Call Company Overview - **Company**: Hansoh Pharma - **Ticker**: 3692.HK - **Market Cap**: HK$217.9 billion / $28.0 billion Key Industry Insights - **Sales Growth for Ameile**: - On-track sales progress for Ameile with a peak sales guidance of Rmb8 billion as a monotherapy, expected to be driven by adjuvant settings over the next two years [1][2] - Incremental sales contribution from adjuvant settings estimated at Rmb2-3 billion, with gradual sales ramp-up anticipated due to the need for expanded academic marketing and digestion of NRDL price cuts in 2026 [2] - **Overseas Development Progress**: - Smooth progress in overseas development for several assets: - GSK has started patient enrollment for global phase 3 clinical trials for HS-20093 (B7H3 ADC) targeting small cell lung cancer (SCLC) [3] - Merck plans to advance HS-10535 (oral GLP-1) to clinical stage by the end of 2025 [3] - Roche is exploring HS-20110 (CDH17 ADC) for colorectal cancer (CRC) [3] - The company aims to secure at least one out-licensing deal annually to generate sustainable collaboration income from upfront and milestone payments [3] - **Innovative Pipeline Deliveries**: - Targeting 8-10 new INDs (Investigational New Drug applications) each year to enhance the pipeline [4] - Focus on early-stage assets including: - HS-20122 (EGFR/cMet ADC) with patient dosing in 1H25 and phase 1 data readout expected in 2026 [4] - First siRNA program aimed at cardiovascular diseases, with IND filing by the end of 2025 [4] - Oral IL-23 currently in phase 1 [4] Financial Metrics and Valuation - **Price Target**: - Buy rating with a 12-month price target of HK$39.93, representing an upside of 8.4% from the current price of HK$36.82 [8][10] - **Revenue Forecasts**: - Projected revenues for the next few years: - 12/24: Rmb12,260.8 million - 12/25E: Rmb14,746.3 million - 12/26E: Rmb15,839.3 million - 12/27E: Rmb17,202.4 million [10] - **EBITDA Estimates**: - Expected EBITDA figures: - 12/24: Rmb4,315.8 million - 12/25E: Rmb5,027.2 million - 12/26E: Rmb4,959.9 million - 12/27E: Rmb5,197.5 million [10] Risks Identified - **Sales Risks**: - Potential for generics sales post VBP (Volume-Based Procurement) to fall below expectations [9] - **Ramp-Up Risks**: - Slower-than-expected ramp-up of novel drugs [9] - **R&D Risks**: - Risks associated with the innovative drug pipeline [9] - **Collaboration Income Risks**: - Below-expected collaboration income from global expansion of the pipeline [9] Conclusion Hansoh Pharma is positioned for growth with a strong pipeline and overseas development initiatives. However, potential risks related to sales performance, drug ramp-up, and R&D must be monitored closely. The company maintains a positive outlook with a solid financial forecast and strategic plans for innovation and market expansion.

Investment Rating - The report maintains a "Buy" rating for several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [30]. Core Insights - The MSCI China Healthcare Index has increased by 59.5% since early 2025, outperforming the MSCI China Index by 24.0%. However, the healthcare sector has recently experienced a 10% pullback, presenting opportunities in undervalued stocks [1]. - The report emphasizes the importance of overseas clinical advancements for authorized innovative drug pipelines, which are expected to be significant catalysts for stock price increases [3]. - The report highlights a recovery in domestic innovative drug research and development demand, driven by a resurgence in capital market financing and an increase in the scale of innovative drug transactions abroad [1][3]. Summary by Sections Industry Overview - The report suggests a more conservative investment approach, focusing on undervalued stocks within the pharmaceutical sector. It notes that the recent healthcare insurance negotiations and the implementation of the 11th batch of centralized procurement have led to reduced market attention [3]. - The report identifies key products to watch in the upcoming healthcare negotiations, including drugs from companies like 信达生物 and 康方生物, among others [3]. Company Recommendations - The report recommends buying shares in 三生制药, 固生堂, 巨子生物, 药明合联, 信达生物, and 中国生物制药, citing their strong potential for growth and favorable market conditions [3]. - Specific companies are highlighted for their promising clinical trial results and strategic partnerships, such as 三生制药's collaboration with Pfizer on global clinical trials [3]. Valuation Metrics - The report provides a valuation table for recommended companies, showing target prices and potential upside percentages. For example, 固生堂 has a target price of 48.28 with a 62% upside potential [2].